Pyrotinib
Refractory Tumor
Shanghai Chest HospitalSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Refractory Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Opb-111077 National University Hospital, Singapore | Phase 2 | CCC |
Gm-Csf Second Affiliated Hospital of Soochow University | Phase 2 | CCC |
Thymalfasin Second Affiliated Hospital of Soochow University | Phase 2 | CCC |
Endostar Second Affiliated Hospital of Soochow University | Phase 2 | CCC |
rc48-adc Shanghai Chest Hospital | Phase 1/2 | CC |
View all 13 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →